SEC Form 4 · accession 0001209191-15-003154
AVEO PHARMACEUTICALS INC · AVEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew D Dallas
Officer — VP, Finance
Period of report
Jan 6, 2015
Accepted (ET)
Jan 8, 2015 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001325879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 6, 2015 | D | 1,485 | $0.00 | D | 18,100 | D | |
| Common StockF3 | Jan 7, 2015 | S | 519 | $0.7998 | D | 17,581 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $0.84 | Jan 6, 2015 | A | 100,000 | A | — | Jan 6, 2025 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1Shares underlying such disposition to the issuer were forfeited by the reporting person pursuant to the terms of an award of restricted stock granted to the reporting person on June 26, 2013 in connection with the determination of the issuer's Compensation Committee that certain specified strategic performance objectives were not met.
- F2The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2013, which was implemented to cover taxable events related to the partial vesting of certain restricted stock.
- F3The price reported in this Column 4 is an average price. The shares were sold in multiple transactions at prices ranging from $0.78 to $0.82, inclusive.
- F4This option vests in equal monthly installments from January 6, 2015 through January 6, 2019.